

Development of BFD1R, an immunomodulatory Live Biotherapeutic Products(LBP) for rheumatoid arthritis

BIFIDO Co., Ltd



IMMUNOLOGY	Preclinical
Product Type	Live Biotherapeutic Products(LBP)
Indication	Rheumatoid Arthritis
Target	Gut (Gut-joint axis)
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • Maintains Th17/Treg cell balance by inhibiting Th17 cell overexpression in autoimmune diseases and maintaining Treg cell expression. • Reduces differentiated Th17 cells and IL-17 cytokine. • Alleviates inflammation in peripheral joint lesions. • Promotes intestinal tight junction and permeability, reducing inflammation in the intestine and throughout the body.
Competitiveness	<ul style="list-style-type: none"> • First-in-class LBP treatment that inhibits disease activity by improving the intestinal environment of rheumatoid arthritis. • Reduce treatment resistance in early-stage RA → Enhance patients' quality of life.
Development Stage	Preclinical stage
Route of Administration	Once daily, Oral Administration